RESUMO
After initial surgery, 240 pre-, peri- or postmenopausal patients with early node-negative breast carcinoma were randomized to receive either no hormone therapy or adjuvant therapy with medroxyprogesterone acetate at high dosage (HD-MPA; 500 mg IM per day times 28 or 500 mg intramuscularly (i.m.) 5 days a week for 5 weeks then 500 mg i.m. twice weekly for the 5 following months. After a median follow-up time of 3 years, relapse-free survival and overall survival appeared significantly improved in the HD-MPA arm. Side effects were tolerable.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Medroxiprogesterona/análogos & derivados , Adulto , Idoso , Antineoplásicos/efeitos adversos , Neoplasias da Mama/cirurgia , Ensaios Clínicos como Assunto , Terapia Combinada , Feminino , Humanos , Medroxiprogesterona/efeitos adversos , Medroxiprogesterona/uso terapêutico , Acetato de Medroxiprogesterona , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Distribuição AleatóriaRESUMO
In a prospective randomized trial comparing CMF to CMF + HD-MPA for primary node positive breast cancer patients, the authors evidenced clear improvement of hematological tolerance (especially of WBC - granulocytes counts) to chemotherapy in the group receiving also hormonotherapy. The design of the trial allowed to give the patients overall high doses of CMF therapy in both arms; in the group receiving HD-MPA significantly higher doses of CMF could be administered (96.3-97.8% for CMF + HD-MPA treated patients vs 89.7-91.1% for CMF alone treated patients). The menopausal status did not influence the results.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Medroxiprogesterona/análogos & derivados , Adulto , Idoso , Ensaios Clínicos como Assunto , Ciclofosfamida/uso terapêutico , Interações Medicamentosas , Feminino , Fluoruracila/uso terapêutico , Hemoglobinas/análise , Humanos , Contagem de Leucócitos , Medroxiprogesterona/uso terapêutico , Acetato de Medroxiprogesterona , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Contagem de Plaquetas , Distribuição AleatóriaRESUMO
The site of active intermittent gastrointestinal (GI) bleeding could not be found in a patient until abdominal scintigrams with indium-111-labeled red cells suggested that the bleeding was in the ascending colon. Right hemicolectomy abolished the hemorrhages. The binding of In-111 to the red cell is such that vascular activity could be clearly seen over a 5-day period. Indium-111-labeled red cells might provide an excellent tracer to locate intermittent active GI bleeding.
